Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients

The objective of the study was the assessment of serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of matrix metalloproteinases 2 (TIMP-2) in patients with colorectal cancer (CRC). The study included 72 CRC patients and 68 healthy subjects. The serum levels of MMP-2 and TIMP-2 were measured using enzyme-linked immunosorbent assay (ELISA) method, whereas tissue expression of MMP-2 and TIMP-2 in cancer cells, interstitial inflammatory cells, and adjacent normal colorectal mucosa were examined by immunohistochemical staining of tumor samples. The serum levels of MMP-2 and TIMP-2 in cancer patients were significantly lower than those in control group, but the percentage of positive immunoreactivity of these proteins were higher in malignant and inflammatory cells as compared to normal tissue. There was a significant correlation between MMP-2 immunoreactivity in inflammatory cells and the presence of distant metastases and between TIMP-2 expression in inflammatory cells and tumor size, nodal involvement, and distant metastases. Area under receiver operating characteristic (ROC) curve (AUC) for serum MMP-2 was higher than for serum TIMP-2. Moreover, positive tissue expression of MMP-2 was a significant prognostic factor for CRC patients’ survival. Our findings suggest that MMP-2 and TIMP-2 might play a role in the process of colorectal cancer invasion and metastasis, but the significance of their interactions with tumor stroma and interstitial inflammatory infiltration in colorectal neoplasia require further elucidation.

[1]  Mei Han,et al.  Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. , 2005, World journal of gastroenterology.

[2]  B. Mroczko,et al.  Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients , 2008, Clinical chemistry and laboratory medicine.

[3]  M. Langenskiöld,et al.  Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer , 2005, International Journal of Colorectal Disease.

[4]  Nitin R. Patel,et al.  ALGORITHM 643: FEXACT: a FORTRAN subroutine for Fisher's exact test on unordered r×c contingency tables , 1986, TOMS.

[5]  B. Mroczko,et al.  Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients. , 2011, Folia histochemica et cytobiologica.

[6]  C. V. D. van de Velde,et al.  Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer , 2006, British Journal of Cancer.

[7]  Y. Nagano,et al.  Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer. , 2008, Oncology reports.

[8]  M. Langenskiöld,et al.  Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation , 2007, International Journal of Colorectal Disease.

[9]  H. Sato,et al.  Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. , 1992, Oncogene.

[10]  T. Wobbes,et al.  Plasma Levels of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-1 Correlate With Disease Stage and Survival in Colorectal Cancer Patients , 2005, Diseases of the colon and rectum.

[11]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[12]  V. Kähäri,et al.  Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.

[13]  C. V. van Noorden,et al.  The role of gelatinases in colorectal cancer progression and metastasis. , 2004, Biochimica et biophysica acta.

[14]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[15]  K. Pavlakis,et al.  The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. , 2008, Anticancer research.

[16]  R. Broll,et al.  Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer , 2006, International Journal of Colorectal Disease.

[17]  E. Gershtein,et al.  Matrix metalloproteinases 2, 3, 13 and their type 2 tissue inhibitor in tumors and plasma of patients with colorectal cancer , 2008, Bulletin of Experimental Biology and Medicine.

[18]  P. E. Van den Steen,et al.  Gelatinase B: a tuner and amplifier of immune functions. , 2001, Trends in immunology.

[19]  T. Krieg,et al.  Tissue Inhibitor of Matrix Metalloproteinase-2 Regulates Matrix Metalloproteinase-2 Activation by Modulation of Membrane-type 1 Matrix Metalloproteinase Activity in High and Low Invasive Melanoma Cell Lines* , 1999, The Journal of Biological Chemistry.

[20]  T. Wobbes,et al.  Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  R. Stenling,et al.  Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. , 2000, Anticancer research.

[22]  Ge Li,et al.  Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer , 2006, BMC Cancer.

[23]  Wei Wu,et al.  [Expression of MMP-2, MMP-9 and collagen type IV and their relationship in colorectal carcinomas]. , 2008, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.

[24]  I. Talbot,et al.  Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. , 1996, Cancer research.

[25]  J. Willett,et al.  Active MMP‐2 effectively identifies the presence of colorectal cancer , 2009, International journal of cancer.

[26]  M. Nowacki,et al.  CRP, TNFα, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients , 2009, Pathology Oncology Research.

[27]  J A Hanley,et al.  Sampling variability of nonparametric estimates of the areas under receiver operating characteristic curves: an update. , 1997, Academic radiology.

[28]  T. Turpeenniemi‐Hujanen,et al.  Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma , 2003, British Journal of Cancer.

[29]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[30]  M. Nowacki,et al.  Clinical Significance of Serum Cytokine Measurements in Untreated Colorectal Cancer Patients: Soluble Tumor Necrosis Factor Receptor Type I – An Independent Prognostic Factor , 2005, Tumor Biology.

[31]  Y. Okada,et al.  TIMP-2 Promotes Activation of Progelatinase A by Membrane-type 1 Matrix Metalloproteinase Immobilized on Agarose Beads* , 1998, The Journal of Biological Chemistry.

[32]  Cornelis F. M. Sier,et al.  MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients , 2012, British Journal of Cancer.